Final-Program-ATS-2023-AP.vp

136

MONDAY • MAY 22

10:24 A Digital Therapeutic For Anxiety Symptoms In Patients With Idiopathic Pulmonary Fibrosis: An Open-label Pilot Clinical Investigation/ M.R. Horton, Baltimore, MD 10:36 Generalizability of Pharmaceutical Randomized Controlled Trials for Idiopathic Pulmonary Fibrosis/ Y. Khor, Heidelberg, Australia 10:48 BMS-986278, an Oral Lysophosphatidic Acid Receptor 1

10:36 Disparities in Hospital Length of Stay Among Severely Ill Patients With Community Acquired Sepsis and Acute Respiratory Failure Across 27 Hospitals/ C.F. Chesley, Philadelphia, PA 10:48 Operationalizing the Social Determinants of Critical Care/ D. Ramadurai, Philadelphia, PA

(LPA1) Antagonist, for Patients With Idiopathic Pulmonary Fibrosis: Results From a Phase 2 Randomized Trial/ T.J. Corte, Sydney, Australia

CLINICAL MINI SYMPOSIUM

BEHAVIORAL • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM TIME TO ACT: INTERVENTIONS TO REDUCE RESPIRATORY HEALTH EFFECTS OF POLLUTANTS

B17

EMERGING DATA ON DISEASE AND SYMPTOM BASED THERAPEUTICS FOR PATIENTS WITH IPF

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Ballroom B (Level 3)

B18

Chairing: M. Kreuter, MD, Heidelberg, Germany S.B. Montesi, MD, Boston, MA J.S. Lee, MD, ATSF, Aurora, CO Featured Speaker: 9:00 Treating Pulmonary Fibrosis: The Future Is Bright/ L. Richeldi, Rome, Italy Oral Presentations: 9:12 PLN-74809 Shows Favorable Safety and Tolerability and Indicates Antifibrotic Activity in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis/ L.H. Lancaster, Nashville, TN 9:24 Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients/ F.A. Woodhead, Seattle, WA 9:36 The Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or Nintedanib/ M.K. Vasakova, Praha, Czech Republic 9:48 Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Preliminary Results of a Systematic Review and Meta-analysis/ A.K.Y. Teoh, Camperdown, Australia 10:00 Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough: A Phase 2 Study/ T.M. Maher, Los Angeles, CA 10:12 The Effect of Oral Nalbuphine Extended Release on Patient-reported Outcome Measures in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough/ T.M. Maher, Los Angeles, CA

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Room 102 A-B (Street Level)

Chairing: N.N. Hansel, MD, MPH, Baltimore, MD G.D. Thurston, DSc, New York, NY J.G. Wang, MD, Columbus, OH Oral Presentations: 9:00 Effects of a Liquefied Petroleum Gas, Continuous Fuel Delivery and Behavioral Messaging Intervention on Linear Growth in Children With Exposure to Household Air Pollution: A Multi-country Randomized Controlled Trial/ W. Checkley, Baltimore, MD 9:12 Antioxidant Intake Modifies Susceptibility to Indoor Air Pollution in Children With Asthma/ R.N. Shade, Baltimore, MD 9:24 Omega-3 Fatty Acids Attenuate Air Pollution Particulate Matter Induced Inflammation and Oxidative Stress in Airway Epithelial Cells/ R.D. Huff, Vancouver, Canada 9:36 Impact of 20 Years of Tobacco Policy, Strategy, and Programs on Chicago’s Adult and Youth Tobacco Use/ A. Patel, Chicago, IL 9:48 AIRWEIGHS: A Randomized Clinical Trial of Indoor Air Cleaners Among Normal and Overweight/Obese Children With Asthma/ A.Y. Qiu, Baltimore, MD 10:00 Reduction in Coking-operation-related Particulate Matter and Pediatric Asthma Emergency Department Visits After Plant Closure - An Interrupted Time Series Analysis/ W. Yu, New York, NY Respiratory Infection From Air Pollution Exposure After Improved Vehicle Emissions Standards in New York State/ D. Croft, Rochester, NY 10:12 Change in Rate of Healthcare Encounters for

ATS 2023 • Washington, DC